CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 6, 2016--
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage biotechnology
company committed to developing potentially transformative gene
therapies for severe genetic diseases and cancer, today announced that
it has commenced an underwritten public offering of $200 million of its
common stock. bluebird bio also intends to grant the underwriters a
30-day option to purchase up to an additional fifteen percent (15%) of
the shares of common stock offered in the public offering. All of the
shares in the proposed offering are to be sold by bluebird bio.
Goldman, Sachs & Co., BofA Merrill Lynch and Cowen and Company are
acting as joint book-running managers of the proposed offering. Wells
Fargo Securities and Wedbush PacGrow are acting as co-managers. The
offering is subject to market and other conditions, and there can be no
assurance as to whether or when the offering may be completed, or as to
the actual size or terms of the offering.
The shares are being offered by bluebird bio pursuant to an
automatically effective shelf registration statement that was previously
filed with the Securities and Exchange Commission (SEC). A preliminary
prospectus supplement relating to and describing the terms of the
offering will be filed with the SEC and will be available on the SEC’s
website at www.sec.gov.
When available, copies of the preliminary prospectus supplement and the
accompanying prospectus relating to these securities may also be
obtained by contacting one of the following: Goldman, Sachs & Co., Attn:
Prospectus Department, 200 West Street, New York, NY 10282, telephone:
(212) 902-1171, facsimile: (212) 902-9316, email: email@example.com;
BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rdfloor,
Charlotte, NC 28255-0001, Attn: Prospectus Department, email: firstname.lastname@example.org;
or Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long
Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by
telephone at (631) 274-2806 or by fax at (631) 254-7140. The final terms
of the offering will be disclosed in a final prospectus supplement to be
filed with the SEC.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of, these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of such state or jurisdiction.
About bluebird bio, Inc.
With its lentiviral-based gene therapy and gene editing capabilities,
bluebird bio has built an integrated product platform with broad
potential application to severe genetic diseases and cancer. bluebird
bio’s gene therapy clinical programs include its Lenti-D™ product
candidate, currently in a Phase 2/3 study, called the Starbeam Study,
for the treatment of cerebral adrenoleukodystrophy, and its LentiGlobin®
BB305 product candidate, currently in four clinical studies for the
treatment of transfusion-dependent beta-thalassemia and severe sickle
cell disease. bluebird bio’s oncology pipeline is built upon the
company’s leadership in lentiviral gene delivery and T cell engineering,
with a focus on developing novel T cell-based immunotherapies, including
chimeric antigen receptor (CAR T) and T cell receptor (TCR) therapies.
bluebird bio’s lead oncology program, bb2121, is an anti-BCMA CAR T
program partnered with Celgene. bb2121 is currently being studied in a
Phase 1 trial for the treatment of relapsed/refractory multiple myeloma.
bluebird bio also has discovery research programs utilizing
megaTALs/homing endonuclease gene editing technologies with the
potential for use across the company’s pipeline.
bluebird bio has operations in Cambridge, Massachusetts, Seattle,
Washington, and Paris, France.
This release contains “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995, including
statements regarding the anticipated final terms, timing and completion
of the proposed offering, and bluebird bio’s existing product candidates
and research programs. Any forward-looking statements are based on
management’s current expectations of future events and are subject to a
number of risks and uncertainties that could cause actual results to
differ materially and adversely from those set forth in or implied by
such forward-looking statements. These risks and uncertainties include,
but are not limited to, risks and uncertainties related to market
conditions and satisfaction of customary closing conditions related to
the proposed public offering, that the preliminary positive results from
our prior and ongoing clinical trials will not continue or be repeated
in our ongoing, planned or expanded clinical trials, the risk that the
changes we have made in the LentiGlobin manufacturing process or the
HGB-206 clinical trial protocol will not result in improved patient
outcomes, the risk that the current or planned clinical trials of
LentiGlobin and Lenti-D will be insufficient to support regulatory
submissions or marketing approval in the United States and European
Union, the risk of cessation or delay of any of the ongoing or
planned clinical studies and/or our development of our product
candidates, the risk of a delay in the enrollment of patients in our
clinical studies, and the risk that any one or more of our product
candidates will not be successfully developed and commercialized. There
can be no assurance that bluebird bio will be able to complete the
proposed public offering on the anticipated terms, or at all. For a
discussion of other risks and uncertainties, and other important
factors, any of which could cause our actual results to differ from
those contained in the forward-looking statements, see the section
entitled “Risk Factors” in our most recent quarterly report on Form
10-Q, as well as discussions of potential risks, uncertainties, and
other important factors in our subsequent filings with the Securities
and Exchange Commission. All information in this press release is as of
the date of the release, and bluebird bio undertakes no duty to update
this information unless required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161206006413/en/
Source: bluebird bio, Inc.
bluebird bio, Inc.
bluebird bio, Inc.
Elizabeth Pingpank, 617-914-8736
Dan Budwick, 973-271-6085